Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders.

Coughlin D, Xie SX, Liang M, Williams A, Peterson C, Weintraub D, McMillan CT, Wolk DA, Akhtar RS, Hurtig HI, Branch Coslett H, Hamilton RH, Siderowf AD, Duda JE, Rascovsky K, Lee EB, Lee VM, Grossman M, Trojanowski JQ, Irwin DJ.

Ann Neurol. 2019 Feb;85(2):259-271. doi: 10.1002/ana.25392. Epub 2019 Jan 7.

2.

The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders.

Irwin DJ, Hurtig HI.

J Alzheimers Dis Parkinsonism. 2018;8(4). pii: 444. doi: 10.4172/2161-0460.1000444. Epub 2018 Aug 10.

3.

Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated.

Robinson JL, Lee EB, Xie SX, Rennert L, Suh E, Bredenberg C, Caswell C, Van Deerlin VM, Yan N, Yousef A, Hurtig HI, Siderowf A, Grossman M, McMillan CT, Miller B, Duda JE, Irwin DJ, Wolk D, Elman L, McCluskey L, Chen-Plotkin A, Weintraub D, Arnold SE, Brettschneider J, Lee VM, Trojanowski JQ.

Brain. 2018 Jul 1;141(7):2181-2193. doi: 10.1093/brain/awy146.

4.

CSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders.

Irwin DJ, Xie SX, Coughlin D, Nevler N, Akhtar RS, McMillan CT, Lee EB, Wolk DA, Weintraub D, Chen-Plotkin A, Duda JE, Spindler M, Siderowf A, Hurtig HI, Shaw LM, Grossman M, Trojanowski JQ.

Neurology. 2018 Mar 20;90(12):e1038-e1046. doi: 10.1212/WNL.0000000000005166. Epub 2018 Feb 21.

5.

Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases.

Sheinerman KS, Toledo JB, Tsivinsky VG, Irwin D, Grossman M, Weintraub D, Hurtig HI, Chen-Plotkin A, Wolk DA, McCluskey LF, Elman LB, Trojanowski JQ, Umansky SR.

Alzheimers Res Ther. 2017 Nov 9;9(1):89. doi: 10.1186/s13195-017-0316-0.

6.

Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia.

Akhtar RS, Xie SX, Chen YJ, Rick J, Gross RG, Nasrallah IM, Van Deerlin VM, Trojanowski JQ, Chen-Plotkin AS, Hurtig HI, Siderowf AD, Dubroff JG, Weintraub D.

PLoS One. 2017 May 25;12(5):e0177924. doi: 10.1371/journal.pone.0177924. eCollection 2017.

7.

Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis.

Irwin DJ, Grossman M, Weintraub D, Hurtig HI, Duda JE, Xie SX, Lee EB, Van Deerlin VM, Lopez OL, Kofler JK, Nelson PT, Jicha GA, Woltjer R, Quinn JF, Kaye J, Leverenz JB, Tsuang D, Longfellow K, Yearout D, Kukull W, Keene CD, Montine TJ, Zabetian CP, Trojanowski JQ.

Lancet Neurol. 2017 Jan;16(1):55-65. doi: 10.1016/S1474-4422(16)30291-5.

8.

Amyloid-Beta Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia.

Akhtar RS, Xie SX, Brennan L, Pontecorvo MJ, Hurtig HI, Trojanowski JQ, Weintraub D, Siderowf AD.

Mov Disord Clin Pract. 2016 Jul-Aug;3(4):367-375. Epub 2016 Jan 5.

9.

Arguing against the proposed definition changes of PD.

Boeve BF, Dickson DW, Duda JE, Ferman TJ, Galasko DR, Galvin JE, Goldman JG, Growdon JH, Hurtig HI, Kaufer DI, Kantarci K, Leverenz JB, Lippa CF, Lopez OL, McKeith IG, Singleton AB, Taylor A, Tsuang D, Weintraub D, Zabetian CP.

Mov Disord. 2016 Nov;31(11):1619-1622. doi: 10.1002/mds.26721. Epub 2016 Aug 5.

10.

Caregiver report of apathy predicts dementia in Parkinson's disease.

Fitts W, Weintraub D, Massimo L, Chahine L, Chen-Plotkin A, Duda JE, Hurtig HI, Rick J, Trojanowski JQ, Dahodwala N.

Parkinsonism Relat Disord. 2015 Aug;21(8):992-5. doi: 10.1016/j.parkreldis.2015.06.009. Epub 2015 Jun 9.

11.

Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy.

Kouri N, Ross OA, Dombroski B, Younkin CS, Serie DJ, Soto-Ortolaza A, Baker M, Finch NCA, Yoon H, Kim J, Fujioka S, McLean CA, Ghetti B, Spina S, Cantwell LB, Farlow MR, Grafman J, Huey ED, Ryung Han M, Beecher S, Geller ET, Kretzschmar HA, Roeber S, Gearing M, Juncos JL, Vonsattel JPG, Van Deerlin VM, Grossman M, Hurtig HI, Gross RG, Arnold SE, Trojanowski JQ, Lee VM, Wenning GK, White CL, Höglinger GU, Müller U, Devlin B, Golbe LI, Crook J, Parisi JE, Boeve BF, Josephs KA, Wszolek ZK, Uitti RJ, Graff-Radford NR, Litvan I, Younkin SG, Wang LS, Ertekin-Taner N, Rademakers R, Hakonarsen H, Schellenberg GD, Dickson DW.

Nat Commun. 2015 Jun 16;6:7247. doi: 10.1038/ncomms8247.

12.

PARK10 is a major locus for sporadic neuropathologically confirmed Parkinson disease.

Beecham GW, Dickson DW, Scott WK, Martin ER, Schellenberg G, Nuytemans K, Larson EB, Buxbaum JD, Trojanowski JQ, Van Deerlin VM, Hurtig HI, Mash DC, Beach TG, Troncoso JC, Pletnikova O, Frosch MP, Ghetti B, Foroud TM, Honig LS, Marder K, Vonsattel JP, Goldman SM, Vinters HV, Ross OA, Wszolek ZK, Wang L, Dykxhoorn DM, Pericak-Vance MA, Montine TJ, Leverenz JB, Dawson TM, Vance JM.

Neurology. 2015 Mar 10;84(10):972-80. doi: 10.1212/WNL.0000000000001332. Epub 2015 Feb 6.

13.

Point pressure sensitivity in early stage Parkinson's disease.

Doty RL, Gandhi SS, Osman A, Hurtig HI, Pawasarat I, Beals E, Chung I, Dubroff J, Newberg A, Ying GS, Leon-Sarmiento FE.

Physiol Behav. 2015 Jan;138:21-7. doi: 10.1016/j.physbeh.2014.09.015. Epub 2014 Oct 22.

PMID:
25447476
14.

Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease.

Kalia LV, Lang AE, Hazrati LN, Fujioka S, Wszolek ZK, Dickson DW, Ross OA, Van Deerlin VM, Trojanowski JQ, Hurtig HI, Alcalay RN, Marder KS, Clark LN, Gaig C, Tolosa E, Ruiz-Martínez J, Marti-Masso JF, Ferrer I, López de Munain A, Goldman SM, Schüle B, Langston JW, Aasly JO, Giordana MT, Bonifati V, Puschmann A, Canesi M, Pezzoli G, Maues De Paula A, Hasegawa K, Duyckaerts C, Brice A, Stoessl AJ, Marras C.

JAMA Neurol. 2015 Jan;72(1):100-5. doi: 10.1001/jamaneurol.2014.2704.

15.

APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease.

Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Hurtig HI, Van Deerlin VM, Ritz B, Rausch R, Rhodes SL, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson AL, Espay AJ, Revilla FJ, Devoto J, Hu SC, Cholerton BA, Wan JY, Montine TJ, Edwards KL, Zabetian CP.

JAMA Neurol. 2014 Nov;71(11):1405-12. doi: 10.1001/jamaneurol.2014.1455.

16.

Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations.

Chahine LM, Qiang J, Ashbridge E, Minger J, Yearout D, Horn S, Colcher A, Hurtig HI, Lee VM, Van Deerlin VM, Leverenz JB, Siderowf AD, Trojanowski JQ, Zabetian CP, Chen-Plotkin A.

JAMA Neurol. 2013 Jul;70(7):852-8. doi: 10.1001/jamaneurol.2013.1274.

17.

A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies.

Nalls MA, Duran R, Lopez G, Kurzawa-Akanbi M, McKeith IG, Chinnery PF, Morris CM, Theuns J, Crosiers D, Cras P, Engelborghs S, De Deyn PP, Van Broeckhoven C, Mann DM, Snowden J, Pickering-Brown S, Halliwell N, Davidson Y, Gibbons L, Harris J, Sheerin UM, Bras J, Hardy J, Clark L, Marder K, Honig LS, Berg D, Maetzler W, Brockmann K, Gasser T, Novellino F, Quattrone A, Annesi G, De Marco EV, Rogaeva E, Masellis M, Black SE, Bilbao JM, Foroud T, Ghetti B, Nichols WC, Pankratz N, Halliday G, Lesage S, Klebe S, Durr A, Duyckaerts C, Brice A, Giasson BI, Trojanowski JQ, Hurtig HI, Tayebi N, Landazabal C, Knight MA, Keller M, Singleton AB, Wolfsberg TG, Sidransky E.

JAMA Neurol. 2013 Jun;70(6):727-35. doi: 10.1001/jamaneurol.2013.1925.

18.

Impairment of script comprehension in Lewy body spectrum disorders.

Gross RG, Camp E, McMillan CT, Dreyfuss M, Gunawardena D, Cook PA, Morgan B, Siderowf A, Hurtig HI, Stern MB, Grossman M.

Brain Lang. 2013 Jun;125(3):330-43. doi: 10.1016/j.bandl.2013.02.006. Epub 2013 Apr 6.

19.

Plasma apolipoprotein A1 as a biomarker for Parkinson disease.

Qiang JK, Wong YC, Siderowf A, Hurtig HI, Xie SX, Lee VM, Trojanowski JQ, Yearout D, B Leverenz J, Montine TJ, Stern M, Mendick S, Jennings D, Zabetian C, Marek K, Chen-Plotkin AS.

Ann Neurol. 2013 Jul;74(1):119-27. doi: 10.1002/ana.23872. Epub 2013 Aug 6.

20.

Neuropathologic substrates of Parkinson disease dementia.

Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Van Deerlin V, Lee VM, Leverenz JB, Montine TJ, Duda JE, Hurtig HI, Trojanowski JQ.

Ann Neurol. 2012 Oct;72(4):587-98. doi: 10.1002/ana.23659. Epub 2012 Oct 4.

21.

Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease.

Hu WT, Holtzman DM, Fagan AM, Shaw LM, Perrin R, Arnold SE, Grossman M, Xiong C, Craig-Schapiro R, Clark CM, Pickering E, Kuhn M, Chen Y, Van Deerlin VM, McCluskey L, Elman L, Karlawish J, Chen-Plotkin A, Hurtig HI, Siderowf A, Swenson F, Lee VM, Morris JC, Trojanowski JQ, Soares H; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2012 Aug 28;79(9):897-905. Epub 2012 Aug 1. Erratum in: Neurology. 2012 Oct 30;79(18):1935.

22.

Genetic influences on cognitive decline in Parkinson's disease.

Morley JF, Xie SX, Hurtig HI, Stern MB, Colcher A, Horn S, Dahodwala N, Duda JE, Weintraub D, Chen-Plotkin AS, Van Deerlin V, Falcone D, Siderowf A.

Mov Disord. 2012 Apr;27(4):512-8. doi: 10.1002/mds.24946. Epub 2012 Feb 16.

23.

Expanding applications of deep brain stimulation: a potential therapeutic role in obesity and addiction management.

Halpern CH, Torres N, Hurtig HI, Wolf JA, Stephen J, Oh MY, Williams NN, Dichter MA, Jaggi JL, Caplan AL, Kampman KM, Wadden TA, Whiting DM, Baltuch GH.

Acta Neurochir (Wien). 2011 Dec;153(12):2293-306. doi: 10.1007/s00701-011-1166-3. Review.

PMID:
21976235
24.

Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy.

Höglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, van Swieten JC, Heutink P, Wszolek ZK, Uitti RJ, Vandrovcova J, Hurtig HI, Gross RG, Maetzler W, Goldwurm S, Tolosa E, Borroni B, Pastor P; PSP Genetics Study Group, Cantwell LB, Han MR, Dillman A, van der Brug MP, Gibbs JR, Cookson MR, Hernandez DG, Singleton AB, Farrer MJ, Yu CE, Golbe LI, Revesz T, Hardy J, Lees AJ, Devlin B, Hakonarson H, Müller U, Schellenberg GD.

Nat Genet. 2011 Jun 19;43(7):699-705. doi: 10.1038/ng.859.

25.

Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease.

Chen-Plotkin AS, Hu WT, Siderowf A, Weintraub D, Goldmann Gross R, Hurtig HI, Xie SX, Arnold SE, Grossman M, Clark CM, Shaw LM, McCluskey L, Elman L, Van Deerlin VM, Lee VM, Soares H, Trojanowski JQ.

Ann Neurol. 2011 Apr;69(4):655-63. doi: 10.1002/ana.22271. Epub 2010 Nov 29.

26.

Current understanding and management of Parkinson disease: five new things.

Morley JF, Hurtig HI.

Neurology. 2010 Nov 2;75(18 Suppl 1):S9-15. doi: 10.1212/WNL.0b013e3181fb3628. Review. No abstract available.

PMID:
21041778
27.

Novel CSF biomarkers for frontotemporal lobar degenerations.

Hu WT, Chen-Plotkin A, Grossman M, Arnold SE, Clark CM, Shaw LM, McCluskey L, Elman L, Hurtig HI, Siderowf A, Lee VM, Soares H, Trojanowski JQ.

Neurology. 2010 Dec 7;75(23):2079-86. doi: 10.1212/WNL.0b013e318200d78d. Epub 2010 Nov 3.

28.

TDP-43 pathology occurs infrequently in multiple system atrophy.

Geser F, Malunda JA, Hurtig HI, Duda JE, Wenning GK, Gilman S, Low PA, Lee VM, Trojanowski JQ.

Neuropathol Appl Neurobiol. 2011 Jun;37(4):358-65. doi: 10.1111/j.1365-2990.2010.01136.x.

29.

A recommended scale for cognitive screening in clinical trials of Parkinson's disease.

Chou KL, Amick MM, Brandt J, Camicioli R, Frei K, Gitelman D, Goldman J, Growdon J, Hurtig HI, Levin B, Litvan I, Marsh L, Simuni T, Tröster AI, Uc EY; Parkinson Study Group Cognitive/Psychiatric Working Group.

Mov Disord. 2010 Nov 15;25(15):2501-7. doi: 10.1002/mds.23362.

30.

Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease.

Weintraub D, Mavandadi S, Mamikonyan E, Siderowf AD, Duda JE, Hurtig HI, Colcher A, Horn SS, Nazem S, Ten Have TR, Stern MB.

Neurology. 2010 Aug 3;75(5):448-55. doi: 10.1212/WNL.0b013e3181ebdd79.

31.

Best surgical practices: a stepwise approach to the University of Pennsylvania deep brain stimulation protocol.

Kramer DR, Halpern CH, Buonacore DL, McGill KR, Hurtig HI, Jaggi JL, Baltuch GH.

Neurosurg Focus. 2010 Aug;29(2):E3. doi: 10.3171/2010.4.FOCUS10103.

PMID:
20672920
32.

Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease.

Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, McCluskey L, Elman L, Karlawish J, Hurtig HI, Siderowf A, Lee VM, Soares H, Trojanowski JQ.

Acta Neuropathol. 2010 Sep;120(3):385-99. doi: 10.1007/s00401-010-0723-9. Epub 2010 Jul 22. Review.

33.

Long-term efficacy of rasagiline in early Parkinson's disease.

Lew MF, Hauser RA, Hurtig HI, Ondo WG, Wojcieszek J, Goren T, Fitzer-Attas CJ.

Int J Neurosci. 2010 Jun;120(6):404-8. doi: 10.3109/00207451003778744.

PMID:
20504210
34.

Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment.

Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, Pickering E, Kuhn M, Chen Y, McCluskey L, Elman L, Karlawish J, Hurtig HI, Siderowf A, Lee VM, Soares H, Trojanowski JQ.

Acta Neuropathol. 2010 Jun;119(6):669-78. doi: 10.1007/s00401-010-0667-0. Epub 2010 Mar 16.

35.

Longitudinal patterns of semantic and episodic memory in frontotemporal lobar degeneration and Alzheimer's disease.

Xie SX, Libon DJ, Wang X, Massimo L, Moore P, Vesely L, Khan A, Chatterjee A, Coslett HB, Hurtig HI, Liang TW, Grossman M.

J Int Neuropsychol Soc. 2010 Mar;16(2):278-86. doi: 10.1017/S1355617709991317. Epub 2009 Dec 11.

36.

Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease.

Weintraub D, Hoops S, Shea JA, Lyons KE, Pahwa R, Driver-Dunckley ED, Adler CH, Potenza MN, Miyasaki J, Siderowf AD, Duda JE, Hurtig HI, Colcher A, Horn SS, Stern MB, Voon V.

Mov Disord. 2009 Jul 30;24(10):1461-7. doi: 10.1002/mds.22571.

37.

Neuropsychological decline in frontotemporal lobar degeneration: a longitudinal analysis.

Libon DJ, Xie SX, Wang X, Massimo L, Moore P, Vesely L, Khan A, Chatterjee A, Coslett HB, Hurtig HI, Liang TW, Grossman M.

Neuropsychology. 2009 May;23(3):337-46. doi: 10.1037/a0014995.

38.

Montreal cognitive assessment performance in patients with Parkinson's disease with "normal" global cognition according to mini-mental state examination score.

Nazem S, Siderowf AD, Duda JE, Have TT, Colcher A, Horn SS, Moberg PJ, Wilkinson JR, Hurtig HI, Stern MB, Weintraub D.

J Am Geriatr Soc. 2009 Feb;57(2):304-8. doi: 10.1111/j.1532-5415.2008.02096.x. Epub 2008 Dec 10.

39.

Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.

Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ; TEMPO Open-label Study Group.

Mov Disord. 2009 Mar 15;24(4):564-73. doi: 10.1002/mds.22402.

PMID:
19086083
40.

Clinical and pathological characteristics of patients with leucine-rich repeat kinase-2 mutations.

Covy JP, Yuan W, Waxman EA, Hurtig HI, Van Deerlin VM, Giasson BI.

Mov Disord. 2009 Jan 15;24(1):32-9. doi: 10.1002/mds.22096.

41.

Clinical reasoning: a 52-year-old woman with subacute hemichorea.

Kranick SM, Price RS, Prasad S, Hurtig HI.

Neurology. 2008 Nov 11;71(20):e59-62. doi: 10.1212/01.wnl.0000334759.72146.39. No abstract available.

PMID:
19001243
42.

Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores.

Mamikonyan E, Moberg PJ, Siderowf A, Duda JE, Have TT, Hurtig HI, Stern MB, Weintraub D.

Parkinsonism Relat Disord. 2009 Mar;15(3):226-31. doi: 10.1016/j.parkreldis.2008.05.006. Epub 2008 Jul 2.

43.

Longitudinal decline in autopsy-defined frontotemporal lobar degeneration.

Grossman M, Xie SX, Libon DJ, Wang X, Massimo L, Moore P, Vesely L, Berkowitz R, Chatterjee A, Coslett HB, Hurtig HI, Forman MS, Lee VM, Trojanowski JQ.

Neurology. 2008 May 27;70(22):2036-45. doi: 10.1212/01.wnl.0000303816.25065.bc. Epub 2008 Apr 16.

44.

Cognitive impairment in Parkinson's disease and dementia with lewy bodies: a spectrum of disease.

Goldmann Gross R, Siderowf A, Hurtig HI.

Neurosignals. 2008;16(1):24-34. Epub 2007 Dec 5. Review.

45.

Distinct antemortem profiles in patients with pathologically defined frontotemporal dementia.

Grossman M, Libon DJ, Forman MS, Massimo L, Wood E, Moore P, Anderson C, Farmer J, Chatterjee A, Clark CM, Coslett HB, Hurtig HI, Lee VM, Trojanowski JQ.

Arch Neurol. 2007 Nov;64(11):1601-9.

PMID:
17998442
46.

Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations.

Chen-Plotkin AS, Yuan W, Anderson C, McCarty Wood E, Hurtig HI, Clark CM, Miller BL, Lee VM, Trojanowski JQ, Grossman M, Van Deerlin VM.

Neurology. 2008 Feb 12;70(7):521-7. Epub 2007 Oct 3.

47.

Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies.

Weintraub D, Hurtig HI.

Am J Psychiatry. 2007 Oct;164(10):1491-8. Review. No abstract available.

48.

Subthalamic nucleus deep brain stimulation for severe idiopathic dystonia: impact on severity, neuropsychological status, and quality of life.

Kleiner-Fisman G, Liang GS, Moberg PJ, Ruocco AC, Hurtig HI, Baltuch GH, Jaggi JL, Stern MB.

J Neurosurg. 2007 Jul;107(1):29-36.

PMID:
17639870
49.

Palliative care in amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis.

Elman LB, Houghton DJ, Wu GF, Hurtig HI, Markowitz CE, McCluskey L.

J Palliat Med. 2007 Apr;10(2):433-57. Review.

PMID:
17472516
50.

Cognitive and motor assessment in autopsy-proven corticobasal degeneration.

Murray R, Neumann M, Forman MS, Farmer J, Massimo L, Rice A, Miller BL, Johnson JK, Clark CM, Hurtig HI, Gorno-Tempini ML, Lee VM, Trojanowski JQ, Grossman M.

Neurology. 2007 Apr 17;68(16):1274-83.

PMID:
17438218

Supplemental Content

Loading ...
Support Center